Last updated 2 months ago

Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab Administered Intravenously in Adult Participants at High Risk of Delayed Graft Function After Kidney Transplantation

450 patients around the world
Available in Brazil, Argentina
AWAKE is a multicenter, prospective study to evaluate the safety and efficacy of ravulizumab in reducing delayed graft function (DGF) in kidney transplant recipients at high risk for DGF. Eligible participants will be randomized in a 1:1 ratio to receive either ravulizumab or placebo intravenously.
Alexion Pharmaceuticals, Inc.
450Patients around the world

This study is for people with

Kidney Transplant

Requirements for the patient

From 18 Years
All Gender

Medical requirements

≥ 18 years of age at the time of signing the informed consent.
Diagnosed with Dialysis-dependent End-Stage Kidney Disease (ESKD).
A candidate for kidney transplant from:
Donation after Circulatory Death (DCD) donor.
High-risk Donation after Brain Death (DBD) donor.
Is to receive a kidney from a donor with category I, II, IV and V Maastricht Classification.
Diagnosed with Acute Kidney Injury (AKI) of Stage 3 severity according to the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines.
Trialtech
About usOur missionOur teamPartnersFAQs
Medical newsLatest newsStudiesInterviewsTestimonials
ProductsUEPM OncoUEPM Physicians
LinksDownloadsCareers
LinkedinInstagramFacebook
Terms and ConditionsPrivacy Policy